AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19852327 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.1 mg
Number of subjects: 60
Study 19852327 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal fentanyl 25 microg
Number of subjects: 60
Study 16808927 — intervention group
Group type: EXPERIMENTAL
Intervention: 480 mg EGb 761
Number of subjects: 107
Study 16808927 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg EGb 761
Number of subjects: 107
Study 16808927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 15448308 — intervention group
Group type: EXPERIMENTAL
Intervention: High elaboration during resistance to persuasion
Number of subjects: 0
Study 15448308 — intervention group
Group type: COMPARATOR
Intervention: Low elaboration during resistance to persuasion
Number of subjects: 0
Study 11820148 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat treatment with diet
Number of subjects: 257
Study 11570304 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator
Number of subjects: 0
Study 11570304 — intervention group
Group type: EXPERIMENTAL
Intervention: thrombolytic therapy
Number of subjects: 0
Study 9260016 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-guided retrograde intubation
Number of subjects: 27
Study 8500240 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (EF)
Number of subjects: 1446
Study 8500240 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak bicycle exercise oxygen consumption (VO2)
Number of subjects: 1446
Study 8500240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiothoracic ratio (CTR)
Number of subjects: 1446
Study 8500240 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular arrhythmias
Number of subjects: 1446
Study 8500240 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma norepinephrine
Number of subjects: 1446
Study 8500240 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma renin activity
Number of subjects: 1446
Study 3694061 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual correction using three anatomical points of reference (iliac crest levelness, vertical appraisal of the spine from the sacral base, levelness of the PSIS dimples)
Number of subjects: 41
Study 3694061 — intervention group
Group type: COMPARATOR
Intervention: X-ray method of measurement
Number of subjects: 41
Study 3694061 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual correction
Number of subjects: 41
Study 1695314 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 11
Study 1695314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31754793 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with pazopanib (800 mg daily for 1 week) and paclitaxel (80 mg/m2 weekly for 18 weeks) followed by maintenance pazopanib
Number of subjects: 14
Study 31754793 — intervention group
Group type: COMPARATOR
Intervention: Single-agent pazopanib
Number of subjects: 14
Study 31138317 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive platform trials
Number of subjects: 0
Study 28988307 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic-absolute exercise (HAT, 50%W max under 15%O2)
Number of subjects: 60
Study 28988307 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic-relative exercise (HRT, 50% heart rate reserve under 15%O2)
Number of subjects: 60
Study 28988307 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxic exercise (NT, 50%W max under 21%O2)
Number of subjects: 60
Study 28988307 — intervention group
Group type: COMPARATOR
Intervention: Hypoxic control (HC, resting under 15%O2)
Number of subjects: 60
Study 28988307 — intervention group
Group type: COMPARATOR
Intervention: Normoxic control (NC, resting under 21%O2)
Number of subjects: 60
Study 26254451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrocaps plus gelatin sponge
Number of subjects: 175
Study 26254451 — intervention group
Group type: COMPARATOR
Intervention: Gelatin sponge
Number of subjects: 175
Study 26254451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrocaps
Number of subjects: 175
Study 23645158 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 infusion (15 mg/kg/h)
Number of subjects: 88
Study 23645158 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 88
Study 22406709 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush-covered Navi Tip FX (Group I)
Number of subjects: 30
Study 22406709 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-vented needle (Group II)
Number of subjects: 30
Study 22406709 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-beveled needle (Group III)
Number of subjects: 30
Study 19023632 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 41
Study 17523581 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple KPT group (two addiction counseling sessions followed by two KPT sessions)
Number of subjects: 59
Study 17523581 — intervention group
Group type: COMPARATOR
Intervention: Single KPT group (two addiction counseling sessions with no additional ketamine therapy)
Number of subjects: 59
Study 15448531 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal group (12-ml/h basal rate, 0.05-ml patient-controlled bolus dose)
Number of subjects: 30
Study 15448531 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus group (8-ml/h basal rate, 4-ml bolus dose)
Number of subjects: 30
Study 15448531 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus group (0.3-ml/h basal rate, 9.9-ml bolus dose)
Number of subjects: 30
Study 15448531 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study 11850998 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV)
Number of subjects: 0
Study 11850998 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 0
Study 11850998 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term NPPV
Number of subjects: 0
Study 9718120 — intervention group
Group type: COMPARATOR
Intervention: AZT monotherapy
Number of subjects: 42
Study 9718120 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT + ddC (Zalcitabine)
Number of subjects: 42
Study 9718120 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT + ddI (Didanosine)
Number of subjects: 42
Study 7491174 — intervention group
Group type: EXPERIMENTAL
Intervention: SPET imaging
Number of subjects: 110
Study 7491174 — intervention group
Group type: COMPARATOR
Intervention: Planar imaging
Number of subjects: 110
Study 7491174 — intervention group
Group type: COMPARATOR
Intervention: Both imaging tests
Number of subjects: 110
Study 2566058 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual appearance and dipstick testing for nitrite and leucocyte esterase
Number of subjects: 418
Study 2566058 — intervention group
Group type: EXPERIMENTAL
Intervention: Various screening tests (visual appearance, microscopy, dipstick for nitrite, leucocyte esterase, protein, and blood, dipstick for nitrite and organisms)
Number of subjects: 418
Study 333862 — intervention group
Group type: COMPARATOR
Intervention: Biphasic hormone combination (Cyclacur) with 2 mg estradiol valerianate for 11 days, followed by 2 mg estradiol valerianate plus 0.5 mg dl‐norgestrel for 10 days, and a 7-day medication-free period.
Number of subjects: 20
Study 31627408 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating copper concentrations
Number of subjects: 139
Study 31627408 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper/zinc ratio
Number of subjects: 139
Study 31627408 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma copper
Number of subjects: 139
Study 31627408 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 139
Study 27353750 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily disposable hydrogel contact lenses worn by CLIDE
Number of subjects: 60
Study 27353750 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily disposable hydrogel contact lenses worn by NO-CLIDE
Number of subjects: 60
Study 26032239 — intervention group
Group type: EXPERIMENTAL
Intervention: Trebananib and Paclitaxel
Number of subjects: 0
Study 26032239 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 0
Study 26032239 — intervention group
Group type: COMPARATOR
Intervention: Other Chemotherapeutic Agents
Number of subjects: 0
Study 23377328 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical product containing 0.5% ellagic acid and 0.1% salicylic acid
Number of subjects: 54
Study 23377328 — intervention group
Group type: COMPARATOR
Intervention: 4% hydroquinone (HQ)
Number of subjects: 54
Study 21187200 — intervention group
Group type: EXPERIMENTAL
Intervention: verum treatment (acupoint ST-34 stimulation)
Number of subjects: 60
Study 21187200 — intervention group
Group type: COMPARATOR
Intervention: control treatment (nonacupoint stimulation)
Number of subjects: 60
Study 19133707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 microg/kg plus 2% prilocaine 3 mg/kg
Number of subjects: 75
Study 19133707 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg plus 2% prilocaine 3 mg/kg
Number of subjects: 75
Study 19133707 — intervention group
Group type: COMPARATOR
Intervention: 2% prilocaine 3 mg/kg
Number of subjects: 75
Study 17382827 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 1721
Study 17382827 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 1721
Study 15499141 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 20 mg/kg/day
Number of subjects: 234
Study 15499141 — intervention group
Group type: COMPARATOR
Intervention: Caffeine citrate 5 mg/kg/day
Number of subjects: 234
Study 11226796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrastromal corneal ring segments (ICRS) of various thicknesses (0.25, 0.30, 0.35, 0.40, or 0.45 mm)
Number of subjects: 107
Study 11226796 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 107
Study 9659527 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard gas mixture
Number of subjects: 20
Study 9659527 — intervention group
Group type: COMPARATOR
Intervention: High-oxygen gas mixture
Number of subjects: 20
Study 9659527 — intervention group
Group type: COMPARATOR
Intervention: Long protocol (30 min waiting time)
Number of subjects: 20
Study 9659527 — intervention group
Group type: EXPERIMENTAL
Intervention: Short protocol (5 min waiting time)
Number of subjects: 20
Study 7718142 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus urinaria
Number of subjects: 88
Study 7718142 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus
Number of subjects: 88
Study 7718142 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus niruri
Number of subjects: 88
Study 7718142 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 88
Study 2729944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole sodium (0.375 g)
Number of subjects: 40
Study 2729944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole sodium (0.750 g)
Number of subjects: 40
Study 2729944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole sodium (1 g)
Number of subjects: 40
Study 2729944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole sodium (2 g)
Number of subjects: 40
Study 2729944 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 40
Study 2729944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole sodium (0.375 g to 2 g)
Number of subjects: 40
Study 30976787 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted edoxaban 60 mg (30 mg for dose reduction)
Number of subjects: 632
Study 30976787 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 632
Study 30976787 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted edoxaban
Number of subjects: 632
Study 29273578 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.1 mg
Number of subjects: 58
Study 29273578 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.3 mg
Number of subjects: 58
Study 29273578 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.6 mg
Number of subjects: 58
Study 29273578 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasiglucagon 1.0 mg
Number of subjects: 58
Study 29273578 — intervention group
Group type: COMPARATOR
Intervention: GlucaGen 0.5 mg
Number of subjects: 58
Study 29273578 — intervention group
Group type: COMPARATOR
Intervention: GlucaGen 1.0 mg
Number of subjects: 58
Study 26727369 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Management of Neonatal and Childhood Illnesses (IMNCI) program
Number of subjects: 0
Study 26727369 — intervention group
Group type: EXPERIMENTAL
Intervention: IMNCI program
Number of subjects: 0
Study 24196558 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass liner (DJBL)
Number of subjects: 79
Study 22366974 — intervention group
Group type: EXPERIMENTAL
Intervention: Femur-first technique (group F)
Number of subjects: 116
Study 22366974 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibia-first technique (group T)
Number of subjects: 116
Study 19397661 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 104
Study 19397661 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarization-sensitive OCT (PS-OCT)
Number of subjects: 104
Study 19397661 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT and PS-OCT
Number of subjects: 104
Study 19397661 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT
Number of subjects: 104
Study 17451280 — intervention group
Group type: EXPERIMENTAL
Intervention: lormetazepam 0.5mg + SHT
Number of subjects: 30
Study 17451280 — intervention group
Group type: COMPARATOR
Intervention: SHT alone
Number of subjects: 30
Study 15170701 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 75
Study 15170701 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral 6 Fr with AngioSeal closure (F+C)
Number of subjects: 75
Study 15170701 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral 4 Fr without closure
Number of subjects: 75
Study 11136281 — intervention group
Group type: EXPERIMENTAL
Intervention: OMC (omeprazole, metronidazole, clarithromycin)
Number of subjects: 892
Study 11136281 — intervention group
Group type: EXPERIMENTAL
Intervention: OFC (omeprazole, furazolidone, clarithromycin)
Number of subjects: 892
Study 11136281 — intervention group
Group type: EXPERIMENTAL
Intervention: OFA (omeprazole, furazolidone, amoxicillin)
Number of subjects: 892
Study 11136281 — intervention group
Group type: EXPERIMENTAL
Intervention: BFC (colloidal bismuth subcitrate, furazolidone, clarithromycin)
Number of subjects: 892
Study 10399513 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 80
Study 10399513 — intervention group
Group type: COMPARATOR
Intervention: Cuffed Oropharyngeal Airway (COPA)
Number of subjects: 80
Study 7527421 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administered at the same time as buserelin-HMG
Number of subjects: 0
Study 7527421 — intervention group
Group type: COMPARATOR
Intervention: No growth hormone (GH) administered
Number of subjects: 0
Study 2537003 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum treatment
Number of subjects: 39
Study 2537003 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 39
Study 2537003 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum treatment (after switching from placebo)
Number of subjects: 39
Study 31646416 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report using EQ-5D-5L
Number of subjects: 726
Study 31646416 — intervention group
Group type: COMPARATOR
Intervention: Proxy-report using EQ-5D-5L (relatives)
Number of subjects: 726
Study 31646416 — intervention group
Group type: COMPARATOR
Intervention: Proxy-report using EQ-5D-5L (staff)
Number of subjects: 726
Study 31646416 — intervention group
Group type: EXPERIMENTAL
Intervention: DEMQOL, EQ-5D-5L, QOL-AD, QUALID measures
Number of subjects: 726
Study 30646929 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA treatment for 4-12 weeks
Number of subjects: 0
Study 30646929 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 4-12 weeks
Number of subjects: 0
Study 28556584 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of prednisone (0.8-1.0 mg/kg/day)
Number of subjects: 40
Study 28556584 — intervention group
Group type: COMPARATOR
Intervention: Medium doses of prednisone (0.5-0.6 mg/kg/day)
Number of subjects: 40
Study 26212603 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus assessment with the Hyperemesis Impact of Symptoms questionnaire and a tailored care plan
Number of subjects: 0
Study 26212603 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 23312689 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formulation of levothyroxine (group 1)
Number of subjects: 42
Study 23312689 — intervention group
Group type: COMPARATOR
Intervention: Tablet formulation of levothyroxine (group 2)
Number of subjects: 42
Study 23312689 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (1 and 2)
Number of subjects: 42
Study 20080830 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (0.25 mg) + Dexamethasone (8 mg) on day 1
Number of subjects: 300
Study 20080830 — intervention group
Group type: COMPARATOR
Intervention: Placebo on days 2 and 3
Number of subjects: 300
Study 20080830 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg b.i.d.) on days 2 and 3
Number of subjects: 300
Study 18389745 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline alone (Group A, n=16)
Number of subjects: 47
Study 18389745 — intervention group
Group type: EXPERIMENTAL
Intervention: lactated Ringer's solution alone (Group B, n=16)
Number of subjects: 47
Study 18389745 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline and Ringer's solution, 1:1 ratio (Group C, n=15)
Number of subjects: 47
Study 16847790 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Leg microprocessor-controlled knee
Number of subjects: 8
Study 16847790 — intervention group
Group type: COMPARATOR
Intervention: Mauch SNS knee
Number of subjects: 8
Study 12477770 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 19
Study 12477770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 19
Study 12477770 — intervention group
Group type: COMPARATOR
Intervention: Control (normolipidaemic)
Number of subjects: 19
Study 11022927 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy (n=76)
Number of subjects: 150
Study 11022927 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (control group, n=74)
Number of subjects: 150
Study 8792046 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension night splint (TNS) in addition to standard treatment (anti-inflammatory medication, Viscoheel sofspot heel cushion, stretching program)
Number of subjects: 32
Study 8792046 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment: anti-inflammatory medication, Viscoheel sofspot heel cushion, stretching program)
Number of subjects: 32
Study 8792046 — intervention group
Group type: COMPARATOR
Intervention: Control group after crossover to TNS
Number of subjects: 32
Study 8315648 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional audiotape
Number of subjects: 54
Study 8315648 — intervention group
Group type: COMPARATOR
Intervention: No tape (control group)
Number of subjects: 54
Study 3736637 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of hyperprolactinemia
Number of subjects: 32
Study 3736637 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 32
Study 29519882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 547
Study 29519882 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 547
Study 29519882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group (after transfer of 25 participants)
Number of subjects: 547
Study 25230304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary anisodamine (1 mg/5 ml) and diltiazem (2 mg/5 ml)
Number of subjects: 108
Study 25230304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary anisodamine and diltiazem
Number of subjects: 108
Study 25230304 — intervention group
Group type: COMPARATOR
Intervention: Saline (5 ml) and diltiazem (2 mg/5 ml)
Number of subjects: 108
Study 22614887 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer added to conventional mortality risk factors
Number of subjects: 1946
Study 22614887 — intervention group
Group type: COMPARATOR
Intervention: Reference model without D-dimer
Number of subjects: 1946
Study 20124139 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin XR, 2000 mg once daily
Number of subjects: 39
Study 20124139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 18841263 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg/day to 8 mg/day)
Number of subjects: 100
Study 18841263 — intervention group
Group type: COMPARATOR
Intervention: metformin (500 mg/day to 2000 mg/day)
Number of subjects: 100
Study 18841263 — intervention group
Group type: COMPARATOR
Intervention: glyburide (5 mg/day to 20 mg/day)
Number of subjects: 100
Study 15932703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxinluo capsule
Number of subjects: 112
Study 15932703 — intervention group
Group type: COMPARATOR
Intervention: Routine drug treatment
Number of subjects: 112
Study 11834429 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting with GH receptor blockade (pegvisomant)
Number of subjects: 10
Study 11834429 — intervention group
Group type: COMPARATOR
Intervention: Fasting without GH receptor blockade
Number of subjects: 10
Study 10612300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccination (5 mcg every 2 weeks for 8 doses, plus 1 i.m. dose at month 12)
Number of subjects: 32
Study 10612300 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccination (20 mcg for 4 doses at months 0, 1, 2, and 12)
Number of subjects: 32
Study 7821102 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg erythromycin
Number of subjects: 10
Study 7821102 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg erythromycin
Number of subjects: 10
Study 7821102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10